Publication Name	World Journal of Gastroenterology
Manuscript ID	16099
Country	Pakistan

Received	2014-12-26 08:53
Peer-Review Started	2014-12-26 16:14
To Make the First Decision	2015-02-10 15:56
Return for Revision	2015-02-13 11:31
Revised
Second Decision	2015-06-03 07:47
Accepted by Journal Editor-in-Chief	2015-06-04 09:33
Accepted by Company Editor-in-Chief	2015-06-10 16:12
Articles in Press	2015-06-10 16:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-25 10:19
Publish the Manuscript Online	2015-08-28 17:04

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Management of hepatitis delta: Need for novel therapeutic options
Manuscript Source	Invited Manuscript
All Author List	Zaigham Abbas and Minaam Abbas
Funding Agency and Grant Number
Corresponding Author	Dr. Zaigham Abbas, FCPS, FRCP, Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Chand Bibi Road, Karachi 75500, Pakistan. drzabbas@gmail.com
Key Words	Hepatitis D virus; Hepatitis delta; Interferon; Lonafarnib; Prenylation inhibitors; Myrcludex
Core Tip	The human sodium taurocholate cotransporting polypeptide (NTCP) has been identified as a functional, preS1-specific receptor for hepatitis B and D virus entry. New antiviral drugs will target this receptor to control hepatitis delta infection. There are already a few approved drugs available in the market with inhibitory effects on NTCP. Interference with host-mediated post-translational changes of proteins that are crucial to the Hepatitis D virus (HDV) life cycle, such as prenylation may become an important tool to prevent HDV replication. These developments are important since pegylated interferon maintains a sustained virological response in just a quarter of all patients.
Publish Date	2015-08-28 17:04
Citation	Abbas Z, Abbas M. Management of hepatitis delta: Need for novel therapeutic options. World J Gastroenterol 2015; 21(32): 9461-9465
URL	http://www.wjgnet.com/1007-9327/full/v21/i32/9461.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i32.9461

Full Article (PDF)	WJG-21-9461.pdf
Full Article (Word)	WJG-21-9461.doc
Manuscript File	16099-Review.docx
Answering Reviewers	16099-Answering reviewers.pdf
Audio Core Tip	16099-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	16099-Conflict-of-interest statement.pdf
Peer-review Report	16099-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	16099-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	16099-Scientific misconduct check.pdf
Scientific Editor Work List	16099-Scientific editor work list.pdf